{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Aileron Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"ALRN"},"Address":{"label":"Address","value":"285 SUMMER STREET UNIT 101, BOSTON, Massachusetts, 2210, United States"},"Phone":{"label":"Phone","value":"+1 617 995-0900"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Aileron Therapeutics Inc a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects."},"CompanyUrl":{"label":"Company Url","value":"https://www.aileronrx.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Andres Brainsky","title":"Vice President-Clinical Development"},{"name":"Manuel C. Alves Aivado","title":"President, Chief Executive Officer &amp; Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}